Stifel resumed coverage of Tandem Diabetes (TNDM) with a Hold rating and $15 price target The firm is concerned about the company’s sequential ramp in Q3 and Q4, with its Q4 revenue estimate slightly below management’s implied guidance. Stifel’s channel checks show the competitive landscape in the durable pump market is increasing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target raised to $16 from $14 at Truist
- Tandem Diabetes price target raised to $15 from $11 at Citi
- Tandem Diabetes announces t:slim X2 insulin pump cleared for use in U.S.
- Leerink says removal of C-peptide requirement would benefit pump market, Tandem
- Tandem Diabetes announces publication of 2IQP study in Diabetes Care